Stanford Health Care
About Stanford Clinical LaboratoryLicensureContact Us

Home
Test Directory

Test Requisitions Specimen Collection
Critical Values
Administrative Department
Clinical DepartmentsDepartment of PathologyEsoteric DepartmentsFeatured Services



AML PROGNOSIS ASSAY, BLOOD

Test Code: AMLP
Description: The AMLP gene encodes a receptor tyrosine kinase that regulates proliferation and differentiation of hematopoietic stem cells. An internal tandem duplication of the AMLP gene (FLT3-ITD) has been reported in nearly 25% of patients with AML. A further 7% of AML patients have a mutation of aspartic acid residue 835 (D835) in the activation loop of the second kinase domain, which leads to constitutive activation. Both AMLP mutations are associated with a poor prognosis. The NPM1 gene encodes nucleophosmin, a nucleolar phoshoprotein that constantly shuttles between the nucleolus and cytoplasm. Insertion mutations in exon 12 of NPM1 occur in approximately one-third of de novo AMLs and confer a favorable prognosis. This assay is based on fluorescent-PCR combined with restriction enzyme digestion, capillary electrophoresis and GeneScan analysis to detect and identify the FLT3-ITD and FLT3-D835 mutations, as well as exon 12 NPM1 insertion mutations, in a single reaction.

 
 


 
Home | About Stanford Clinical Laboratories | Careers | Contact Us | Legal Notices & Disclaimer